Proceeds from the Series C financing will be used to progress Orchard's three most advanced clinical programs: OTL-101 for adenosine deaminase severe combined immunodeficiency (ADA-SCID), OTL-200 for metachromatic leukodystrophy (MLD) and OTL-103 for Wiskott--Aldrich syndrome (WAS) towards registration and commercialization. The funding will also support the clinical and preclinical development of the company's rare disease gene therapy pipeline.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

101 Seaport Blvd. 7th Floor
Boston, MA 02210
USA

Phone

Undisclosed

Website

www.orchard-tx.com

Email Address

[email protected]

Overview

Orchard Therapeutics (Nasdaq: ORTX) is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.

Profile

Social Media

Orchard Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Bobby Gaspar

Chief Financial Officer

Frank Thomas

Chief Medical Officer

Andrea Spezzi

VP - Bus. Development

Adrien Lemoine

VP - General Counsel

John Ilett

VP - Human Resources

John Cerio

VP - Regulatory Affairs

Anne Dupraz-Poiseau

Browse more venture capital transactions:

Prev: 8/14/2018: HawkEye 360 venture capital transaction
Next: 8/14/2018: Infinite Analytics venture capital transaction

Share this article

About Database of VC Transactions

We do our best to record all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary